Membranous nephropathy (MN) accounts for 9.89% of the total number of primary glomerulonephritis, the typical pathological changes are the deposition of immune complexes under the glomerular epithelium and diffuse thickening of the glomerular basement membrane, the cause of the disease is not named is called primary membranous nephropathy (IMN), the clinical manifestations of nephrotic syndrome or massive proteinuria, about 20-55% of patients with microscopic hematuria, generally no carnaroscopic hematuria, often in the onset of 5 to It is a common pathological type of refractory nephrotic syndrome with progressive renal function impairment after 5 to 10 years of onset. The latest data show that IMN has become the second primary glomerular disease after IgA nephropathy, and its proportion has increased in recent years, so it is important to find effective treatment. Although the pathogenesis of primary membranous nephropathy is not completely clear, it is recognized that the disease is caused by autoantibodies against certain antigens on the glomerular epithelial cell membranes that bind to the antigens and then shed and settle under the epithelial cells, and then activate the complement. Western medicine advocates hormonal and cytotoxic drug therapy for this disease, but long-term hormonal and cytotoxic drug therapy can cause immune tolerance and various complications such as thromboembolism and hyperlipidemia, and it is very easy to relapse, so the treatment is not effective. In 2004, Perna et al. conducted a Meta-analysis of l8 randomized controlled clinical studies of hormonal and cytotoxic drugs used to treat membranous nephropathy over nearly 30 years and concluded that immunosuppressive therapy did not improve long-term survival and renal survival in patients with membranous nephropathy and that there was a lack of strong evidence for its ability to improve long-term outcomes. The publication of this article questions the effectiveness of hormonal and cytotoxic drugs in membranous nephropathy from the perspective of evidence-based medicine, and signals that the time has come to discover and develop new concepts for the treatment of membranous nephropathy. In Chinese medicine, there is no name of “membranous nephropathy”, but according to its main symptoms, it can be classified as “edema” and “turbidity of urine”. Chinese medicine has achieved good results in the treatment of this disease, and has its unique advantages in many aspects. However, there are also problems such as complicated and inconsistent identification and typing, which prevent the formation of a series of prescriptions suitable for most IMN patients, which seriously limits the large-scale promotion of Chinese medicine. In recent years, Prof. Lu Renhe has proposed the theory of “kidney luo Y obstruction” based on the theory of luo disease and Y obstruction in traditional Chinese medicine, combined with the modern medical understanding of kidney anatomy, physiology and pathology, so that the Chinese medical pathogenesis of kidney disease can be more comprehensively and systematically described. With reference to the ancient literature and the theory of “kidney luo Y obstruction”, we believe that this disease is caused by deficiency of kidney qi and obstruction of kidney luo, which is one of the pathological products of luo disease. It was pointed out that the deficiency of kidney qi and obstruction of kidney ligaments in the process of IMN development is a constant part of the disease, and is the fundamental pathogenesis of various complications. Under the guidance of this theory, the basic treatment principle of primary membranous nephropathy was established, which is to benefit Qi, invigorate Blood, pass through the ligaments and eliminate Y. The empirical formula of Yi Qi Tongluo Drink (Astragalus, Angelicae, leech, turtle nail and Curcuma longa, etc.) was developed.